| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT04073966 MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly… |
Enrollment reopened |
| 2026-08-15 | NCT04073966 MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly… |
Enrollment increased: 15 -> 20 participants |
| 2026-08-15 | NCT04073966 MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly… |
date change Primary completion pushed: 2027-05-28 -> 2028-05-31 |
| 2026-08-15 | NCT04073966 MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly… |
date change Completion pushed: 2027-05-28 -> 2029-05-31 |
| 2026-08-14 | NCT06618300 Streamlined Resin Y90 Radiation Segmentectomy for Small HCC |
overall status: Enrolling by Invitation → Active, Not Recruiting |
| 2026-08-07 | NCT06090864 ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells |
date change Primary completion pushed: 2026-07-01 -> 2028-08-03 |
| 2026-08-07 | NCT06090864 ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells |
date change Completion pushed: 2031-07-01 -> 2033-07-01 |
| 2026-08-04 | NCT07634653 Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic… |
Recruitment opened |
| 2026-08-01 | NCT03696784 Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma |
Primary endpoint(s) modified |
| 2026-08-01 | NCT03696784 Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma |
Enrollment reduced: 19 -> 12 participants |
| 2026-07-31 | NCT04585893 Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi |
Trial completed |
| 2026-07-30 | NCT03264131 BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma |
Trial completed |
| 2026-07-30 | NCT03264131 BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma |
date change Completion moved earlier: 2028-12-15 -> 2025-12-15 |
| 2026-07-28 | NCT05754749 Comparison of CE-DBT and MRI in Patients With Known Breast Lesions |
critical Trial terminated |
| 2026-07-28 | NCT05754749 Comparison of CE-DBT and MRI in Patients With Known Breast Lesions |
critical Trial terminated: Funding unavailable |
| 2026-07-28 | NCT05754749 Comparison of CE-DBT and MRI in Patients With Known Breast Lesions |
Enrollment reduced: 20 -> 4 participants |
| 2026-07-28 | NCT05754749 Comparison of CE-DBT and MRI in Patients With Known Breast Lesions |
date change Primary completion moved earlier: 2026-08-22 -> 2026-05-20 |
| 2026-07-28 | NCT05754749 Comparison of CE-DBT and MRI in Patients With Known Breast Lesions |
date change Completion moved earlier: 2026-08-22 -> 2026-05-20 |
| 2026-07-24 | NCT06073067 GRID Therapy for Extremity Soft Tissue Sarcoma |
date change Primary completion pushed: 2026-08-15 -> 2026-11-10 |
| 2026-07-24 | NCT06073067 GRID Therapy for Extremity Soft Tissue Sarcoma |
date change Completion pushed: 2026-08-15 -> 2027-11-10 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-03 | NCT07740941 NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT04083495 | CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma | Peripheral T Cell Lymphoma | Recruiting |
| NCT03977233 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting |
| NCT07278557 | Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia | Head and Neck Cancer | Recruiting |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | Lung Cancer | Recruiting |
| NCT06902311 | Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous… | Breast Cancer | Recruiting |
| NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | Breast Cancer | Recruiting |
| NCT07276880 | Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion… | Breast Cancer | Recruiting |
| NCT06727773 | Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of… | Breast Cancer | Recruiting |
| NCT05472792 | Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation… | Breast Cancer | Recruiting |
| NCT05145400 | Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT07225114 | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging | Breast Cancer | Recruiting |
| NCT07340541 | Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | Breast Cancer | Recruiting |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | Bladder Cancer | Active, Not Recruiting |
| NCT05366166 | Pembrolizumab Plus Olaparib in LA-HNSCC | Squamous Cell Carcinoma of Head and Neck | Active, Not Recruiting |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and… | Carcinoma, Squamous Cell | Active, Not Recruiting |
| NCT07484139 | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in… | Oral Cavity Squamous Cell Carcinoma | Not Yet Recruiting |
| NCT07545746 | Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in… | HIV Infections | Not Yet Recruiting |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1… | Endometrial Cancer | Not Yet Recruiting |
| NCT05911321 | Isa-Pom-Dex in Elderly/Frail Subjects With RRMM | Multiple Myeloma | Active, Not Recruiting |
| NCT04548648 | A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | Central Nervous System Lymphoma | Active, Not Recruiting |
| NCT03529422 | Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN | Larynx | Active, Not Recruiting |
| NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | Leukemia Acute Myeloid | Not Yet Recruiting |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… | Lung Cancer | Not Yet Recruiting |
| NCT07685938 | Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease | Chest Wall Tumor | Not Yet Recruiting |
| NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors | Lung Cancer | Not Yet Recruiting |